Clinical utility of genotyping the 677C>T variant of methylenetetrahydrofolate reductase in humans is decreased in the post-folic acid fortification era.

Moderate hyperhomocysteinemia is associated with many diseases. Major factors affecting plasma total homocysteine (tHcy) concentrations include folate concentrations and polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene. Because U.S.-mandated fortification of grain products with folic acid has improved folate and tHcy status in Americans, we investigated the effect of the MTHFR 677C>T variant before and after fortification. We determined tHcy and folate concentrations in sera from 844 Caucasian and 587 African American participants in the Coronary Artery Risk Development in Young Adults study before and after fortification and we genotyped the MTHFR 677C>T variant. MTHFR 677TT homozygotes had higher (P < 0.01) tHcy concentrations both before and after fortification compared with MTHFR 677CC homozygotes. However, the difference between these 2 genotypes decreased from 2.5 micromol/L before fortification to <0.7 micromol/L postfortification (P < 0.01). In addition, the prevalence of moderate hyperhomocysteinemia (tHcy > 13 micromol/L) in 677TT homozygotes decreased from 33% before fortification to 12% postfortification (P < 0.01). Using a cutoff value of 13 micromol/L to define moderate hyperhomocysteinemia, the sensitivity of the MTHFR 677TT genotype to predict elevations in homocysteine was low (approximately 30%) both before and after folic acid fortification. Increasing the cutoff from 13 to 19 micromol/L increased the sensitivity of the assay before fortification to 62% but decreased the sensitivity to 17% postfortification. We conclude that after folic acid fortification in the US, measurement of tHcy rather than genotyping of MTHFR 677TT should be used as the primary assay for the diagnosis and monitoring of moderate hyperhomocysteinemia.

[1]  H. Blom,et al.  Folate, Homocysteine and Neural Tube Defects: An Overview , 2001, Experimental biology and medicine.

[2]  K. Hudson.  Genetic Testing Oversight , 2006, Science.

[3]  D. Wald,et al.  Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis , 2002, BMJ : British Medical Journal.

[4]  S. Lewis,et al.  Meta-analysis of MTHFR 677C→ T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? , 2005, BMJ : British Medical Journal.

[5]  Per Magne Ueland,et al.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.

[6]  P. Wilson,et al.  Folic acid intake from fortification in United States exceeds predictions. , 2002, The Journal of nutrition.

[7]  P. Wilson,et al.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. , 1993, JAMA.

[8]  S. Vollset,et al.  The methylenetetrahydrofolate reductase 677C-->T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. , 2007, American journal of human genetics.

[9]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[10]  R. Matthews,et al.  Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification , 1994, Nature Genetics.

[11]  Quanhe Yang,et al.  5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. , 2000, American journal of epidemiology.

[12]  A. Folsom,et al.  Elevated Homocysteine Is Associated With Reduced Regional Left Ventricular Function: The Multi-Ethnic Study of Atherosclerosis , 2006, Circulation.

[13]  S B Hulley,et al.  CARDIA: study design, recruitment, and some characteristics of the examined subjects. , 1988, Journal of clinical epidemiology.

[14]  P. Wilson,et al.  The effect of folic acid fortification on plasma folate and total homocysteine concentrations. , 1999, The New England journal of medicine.

[15]  Xiping Xu,et al.  Efficacy of folic acid supplementation in stroke prevention: a meta-analysis , 2007, The Lancet.

[16]  M. Tsai.  Moderate hyperhomocysteinemia and cardiovascular disease. , 2000, The Journal of laboratory and clinical medicine.

[17]  C. Stehouwer,et al.  Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation , 2005, Clinical chemistry and laboratory medicine.

[18]  H. Blom,et al.  Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease , 2002, Pharmacological Reviews.

[19]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[20]  S. Caudill,et al.  Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. , 2005, The American journal of clinical nutrition.

[21]  Farzaneh A. Sorond,et al.  The role of homocysteine in multisystem age-related problems: a systematic review. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[22]  J. Osterloh,et al.  Trends in circulating concentrations of total homocysteine among US adolescents and adults: findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys. , 2008, Clinical chemistry.

[23]  S. S. Kang,et al.  Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. , 1988, Metabolism: clinical and experimental.

[24]  K. Pietrzik,et al.  Vitamins B12, B6 and folate as determinants of homocysteine concentration in the healthy population , 1998, European Journal of Pediatrics.

[25]  B. Steen,et al.  Reduction of plasma homocysteine and serum methylmalonate concentrations in apparently healthy elderly subjects after treatment with folic acid, vitamin B12 and vitamin B6: a randomised trial , 2003, European Journal of Clinical Nutrition.